| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| So-Young Moon, Sang-Soo Lee, Yoon-Ho Hon. Muscle atrophy in muscle-specific tyrosine kinase (MuSK)-related myasthenia gravis. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia. vol 18. issue 9. 2011-11-23. PMID:21741841. |
muscle atrophy in muscle-specific tyrosine kinase (musk)-related myasthenia gravis. |
2011-11-23 |
2023-08-12 |
Not clear |
| So-Young Moon, Sang-Soo Lee, Yoon-Ho Hon. Muscle atrophy in muscle-specific tyrosine kinase (MuSK)-related myasthenia gravis. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia. vol 18. issue 9. 2011-11-23. PMID:21741841. |
myasthenia gravis (mg) with muscle-specific tyrosine kinase (musk) antibody (musk-mg) is often associated with prominent facial and bulbar muscle atrophy. |
2011-11-23 |
2023-08-12 |
Not clear |
| Nils Erik Gilhus, Jone F Owe, Jana Midelfart Hoff, Fredrik Romi, Geir Olve Skeie, Johan A Aarl. Myasthenia gravis: a review of available treatment approaches. Autoimmune diseases. vol 2011. 2011-11-10. PMID:22007295. |
patients with autoimmune myasthenia gravis (mg) should be further classified before initiating therapy, as treatment response varies for ocular versus generalised, early onset versus late onset, and acetylcholine receptor antibody positive versus musk antibody positive disease. |
2011-11-10 |
2023-08-12 |
Not clear |
| Masakatsu Motomur. [Standard treatment for late-onset myasthenia gravis in Japan]. Rinsho shinkeigaku = Clinical neurology. vol 51. issue 8. 2011-11-03. PMID:21878723. |
myasthenia gravis (mg) is caused by the failure of neuromuscular transmission mediated by autoantibodies against acetylcholine receptors (achr) and muscle-specific receptor tyrosine kinase (musk). |
2011-11-03 |
2023-08-12 |
Not clear |
| Vasiliki Zouvelou, Michael Rentzos, Panagiotis Toulas, Ioannis Evdokimidi. MRI evidence of early muscle atrophy in MuSK positive myasthenia gravis. Journal of neuroimaging : official journal of the American Society of Neuroimaging. vol 21. issue 3. 2011-10-28. PMID:20002967. |
mri evidence of early muscle atrophy in musk positive myasthenia gravis. |
2011-10-28 |
2023-08-12 |
Not clear |
| Giovanna Cenacchi, Valentina Papa, Papa Valentina, Marina Fanin, Fanin Marina, Elena Pegoraro, Pegoraro Elena, Corrado Angelini, Angelini Corrad. Comparison of muscle ultrastructure in myasthenia gravis with anti-MuSK and anti-AChR antibodies. Journal of neurology. vol 258. issue 5. 2011-09-23. PMID:21088848. |
patients with myasthenia gravis (mg) with antibodies to muscle-specific receptor tyrosine kinase (musk) differ from acetylcholine receptor (achr)-positive mg patients, as they frequently present with severe oculobulbar muscle weakness or with neck, shoulder, and respiratory muscle involvement. |
2011-09-23 |
2023-08-12 |
Not clear |
| Kinji Ohn. [Genetic defects and disorders at the neuromuscular junction]. Brain and nerve = Shinkei kenkyu no shinpo. vol 63. issue 7. 2011-08-25. PMID:21747136. |
achr, musk, and lrp4 are also targets of auto-antibodies in myasthenia gravis. |
2011-08-25 |
2023-08-12 |
Not clear |
| Tetsuro Konish. [Myasthenia gravis with anti-acetylcholine receptor antibody or anti-muscle specific kinase antibody]. Brain and nerve = Shinkei kenkyu no shinpo. vol 63. issue 7. 2011-08-25. PMID:21747139. |
patients with myasthenia gravis (mg) are divided into 3 groups: anti-acetylcholine receptor antibody-positive mg (achr mg), anti-muscle specific kinase antibody-positive mg (musk mg), and achr-and musk-negative mg (double seronegative mg; double snmg). |
2011-08-25 |
2023-08-12 |
Not clear |
| Satoshi Kuwabar. [Neurophysiologic assessment of disorders affecting the neuromuscular junction]. Brain and nerve = Shinkei kenkyu no shinpo. vol 63. issue 7. 2011-08-25. PMID:21747141. |
myasthenia gravis (mg) with anti-acetylcholine receptor (achr) antibodies, is the most common nmj disorder, and ~5% of myasthenia patients are positive for anti-muscle specific kinase (musk) antibodies. |
2011-08-25 |
2023-08-12 |
Not clear |
| Jeffrey T Guptill, Donald B Sanders, Amelia Evol. Anti-MuSK antibody myasthenia gravis: clinical findings and response to treatment in two large cohorts. Muscle & nerve. vol 44. issue 1. 2011-08-22. PMID:21674519. |
myasthenia gravis (mg) patients with autoantibodies to muscle-specific tyrosine kinase (musk) represent a distinct subset of those with this disease. |
2011-08-22 |
2023-08-12 |
Not clear |
| Anna Rostedt Punga, Shuo Lin, Filippo Oliveri, Sarina Meinen, Markus A Rüeg. Muscle-selective synaptic disassembly and reorganization in MuSK antibody positive MG mice. Experimental neurology. vol 230. issue 2. 2011-08-15. PMID:21565192. |
musk antibody seropositive (musk+) myasthenia gravis (mg) patients present a distinct selective fatigue, and sometimes atrophy, of bulbar, facial and neck muscles. |
2011-08-15 |
2023-08-12 |
mouse |
| R N Cole, N Ghazanfari, S T Ngo, O L Gervásio, S W Reddel, W D Phillip. Patient autoantibodies deplete postsynaptic muscle-specific kinase leading to disassembly of the ACh receptor scaffold and myasthenia gravis in mice. The Journal of physiology. vol 588. issue Pt 17. 2011-06-20. PMID:20603331. |
daily injections of igg from four musk autoantibody-positive myasthenia gravis patients (musk igg; 45 mg day(1)i.p. |
2011-06-20 |
2023-08-12 |
mouse |
| Beth Stein, Shawn J Bir. Rituximab in the treatment of MuSK antibody-positive myasthenia gravis. Journal of clinical neuromuscular disease. vol 12. issue 3. 2011-05-26. PMID:21321497. |
rituximab in the treatment of musk antibody-positive myasthenia gravis. |
2011-05-26 |
2023-08-12 |
Not clear |
| Nazanin Ghazanfari, Kristine J Fernandez, Yui Murata, Marco Morsch, Shyuan T Ngo, Stephen W Reddel, Peter G Noakes, William D Phillip. Muscle specific kinase: organiser of synaptic membrane domains. The international journal of biochemistry & cell biology. vol 43. issue 3. 2011-05-18. PMID:20974278. |
the importance of musk as a synapse organiser is highlighted by cases of autoimmune myasthenia gravis in which musk autoantibodies can deplete musk from the postsynaptic membrane, leading to complete disassembly of the adult nmj. |
2011-05-18 |
2023-08-12 |
Not clear |
| Kathleen Vrolix, Erik H Niks, Rozen Le Panse, Monique M van Ostaijen-Ten Dam, Anne-Hilde Muris, Cornelia M Jol-van der Zijde, Maarten J D van Tol, Mario Losen, Peter C Molenaar, Everardus J J van Zoelen, Sonia Berrih-Aknin, Marc H De Baets, Jan J G M Verschuuren, Pilar Martínez-Martíne. Reduced thymic expression of ErbB receptors without auto-antibodies against synaptic ErbB in myasthenia gravis. Journal of neuroimmunology. vol 232. issue 1-2. 2011-05-17. PMID:21168922. |
in myasthenia gravis (mg), the neuromuscular transmission is impaired mainly by auto-antibodies against the acetylcholine receptor (achr) or musk. |
2011-05-17 |
2023-08-12 |
Not clear |
| Osamu Higuchi, Johko Hamuro, Masakatsu Motomura, Yuji Yamanash. Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis. Annals of neurology. vol 69. issue 2. 2011-05-11. PMID:21387385. |
myasthenia gravis (mg) is an autoimmune disease of the neuromuscular junction, where acetylcholine receptor (achr), muscle-specific kinase (musk), and low-density lipoprotein (ldl) receptor-related protein 4 (lrp4) are essential. |
2011-05-11 |
2023-08-12 |
Not clear |
| Uma Sundar, Preeti Shaunbhag, Yogesh Lakkas, Makardhwaj Shrivastava, Amit Shah, Meghana Vaidya, Dnyaneswar Asol. Experience with patients with anti-MUSK antibody positive myasthenia gravis. The Journal of the Association of Physicians of India. vol 58. 2011-05-04. PMID:21510119. |
the association of muscle tyrosine kinase (musk) antibody with recurrent bulbar weakness in acetylcholine receptor antibody (ach-r ab) negative myasthenia gravis (mg) has been well documented. |
2011-05-04 |
2023-08-12 |
Not clear |
| T Kuntzer, A Carota, J Novy, M Cavassini, R A Du Pasquie. Rituximab is successful in an HIV-positive patient with MuSK myasthenia gravis. Neurology. vol 76. issue 8. 2011-04-08. PMID:21339503. |
rituximab is successful in an hiv-positive patient with musk myasthenia gravis. |
2011-04-08 |
2023-08-12 |
Not clear |
| Jeffrey T Guptill, Donald B Sander. Update on muscle-specific tyrosine kinase antibody positive myasthenia gravis. Current opinion in neurology. vol 23. issue 5. 2010-12-14. PMID:20613516. |
important concepts regarding the pathogenesis, clinical features, diagnosis and treatment of muscle-specific tyrosine kinase (musk) antibody positive myasthenia gravis will be reviewed. |
2010-12-14 |
2023-08-12 |
Not clear |
| Alejandro M Gomez, Joost Van Den Broeck, Kathleen Vrolix, Sofie P Janssen, Marijke A M Lemmens, Eline Van Der Esch, Hans Duimel, Peter Frederik, Peter C Molenaar, Pilar Martínez-Martínez, Marc H De Baets, Mario Lose. Antibody effector mechanisms in myasthenia gravis-pathogenesis at the neuromuscular junction. Autoimmunity. vol 43. issue 5-6. 2010-11-30. PMID:20380584. |
myasthenia gravis (mg) is an autoimmune disorder caused by autoantibodies that are either directed to the muscle nicotinic acetylcholine receptor (achr) or to the muscle-specific tyrosine kinase (musk). |
2010-11-30 |
2023-08-12 |
human |